SeLux Diagnostics
Latest round
- Series C
Last raised
- Feb 2022
Total raised
- $72M
Investors
- 4
About SeLux Diagnostics
Founded in 2014 and based in Massachusetts, US, SeLux Diagnostics, Inc. develops a phenotyping platform for treating infectious diseases. As of 2024, the company is headed by its CEO Steve Lufkin. The company was co-founded by Eric Stern and Aleksandar Vacic. Selux Diagnostics' product is the Selux NGP System which provides automated aminotransferase (AST) results and personalized therapy results for all patients suffering from infectious disease. Diagnostic results are delivered by this technique in the same shift as positive blood cultures. Comprehensive testing for all sample types and antibiotics is offered by the Selux NGP System.
Who invested in SeLux Diagnostics
4 investors across 2 rounds
See all investors in SeLux Diagnostics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about SeLux Diagnostics
Who invested in SeLux Diagnostics?
SeLux Diagnostics has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SeLux Diagnostics raised?
SeLux Diagnostics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did SeLux Diagnostics last raise money?
SeLux Diagnostics's most recent round on record is a Series C, in Feb 2022.
What does SeLux Diagnostics do?
Founded in 2014 and based in Massachusetts, US, SeLux Diagnostics, Inc.
Where is SeLux Diagnostics headquartered?
SeLux Diagnostics is headquartered in US.
Which VCs invest in companies like SeLux Diagnostics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at SeLux Diagnostics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like SeLux Diagnostics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.